top
Please input keywords
研究提携
オープン​イノベーションによる革新的な新薬の研究開発
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Various drug modalities
Disclosed Partners
Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.